Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Last trade$2.03
Day change-$0.015 (-0.74%)
Day range$1.99 – $2.05
Volume135,282
Market cap$193M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for CGEN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for CGEN.
Recent news
Company coverage with links to the original publishers.
Compugen reported Q3 2026 results with revenue of $3.8 million and net loss of $5.8 million. The company completed enrollment in its MAIA-Ovarian trial for COM701 with data expected by end of Q1 2027. Partnered programs with AstraZeneca (rilvegostomig) and Gilead (GS-0321) continue advancing, with rilvegostomig in 12 Phase III trials. The company introduced UnigenX, expanding its discovery platform into tumor-associated antigens for T-cell engagers. Cash runway extends into 2029 with $117.5 million in cash and equivalents.
Nuvation Bio reported a quarterly loss of $0.12 per share, missing the consensus estimate of $0.11 loss, representing a -9.09% earnings surprise. However, the company exceeded revenue expectations with $44.95 million, surpassing estimates by 32.33% and showing 242% year-over-year growth. The stock has underperformed significantly, down 47.7% year-to-date versus the S&P 500's 10.6% gain. Zacks assigned the stock a Hold rating (Rank #3) with mixed estimate revision trends.
BioMarin Pharmaceutical (BMRN) reported quarterly earnings of $0.23 per share, significantly beating the consensus estimate of a loss of $0.09 per share, representing a +355.56% earnings surprise. Revenue reached $1.02 billion, slightly missing estimates by 0.23%. The company has surpassed EPS estimates three times over the last four quarters. However, BMRN shares have underperformed the market, down 1.6% year-to-date versus the S&P 500's 10.7% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revision trends.
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.